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Abstract
Background: To analyze articles that studied patients submitted to diphosphonates therapy and who received den-
tal implants before, during or after bisphosphonate (BP) treatment, compared to healthy patients, analyzing the 
increase of failure and loss of implants or bisphosphonate related osteonecrosis of the jaw (BRONJ) incidence.
Material and Methods: The Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 
statement was used in this study. The clinical question in “PICO” format was: In patients under bisphosphonate 
therapy, do dental implants placement, compared to healthy patients, increase the failure and loss of implants or 
bisphosphonate related osteonecrosis of the jaw incidence? PubMed/MEDLINE was searched for articles publis-
hed up until April 15, 2015 using a combination of MeSH terms and their Entry terms. 
Results: The search resulted in 375 articles. After selection according to the eligibility criteria, 15 studies fulfilled 
were included (eight retrospective, one prospective and six case series), with a total of 1339 patients analyzed, 3748 
implants placed, 152 loss of implants and 78 cases of BRONJ. 
Conclusions: Due to the lack of randomized clinical trials looking at this theme, further studies with longer 
follow-up are needed to elucidate the remaining questions. Thus, it is wise to be careful when planning dental 
implant surgery in patients undergoing bisphosphonate therapy because of the risk of developing BRONJ as well 
as occurring failure of implant. Moreover, complete systemic condition of the patient must be also taking into 
considering when such procedures are performed.
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Introduction
Bisphosphonates (BPs) are pyrophosphate analogues 
with high affinity for the bone hydroxyapatite.  Due to 
their pharmacological effects on the bone, they play an 
important role on skeletal disorders with enhanced or 
imbalanced bone remodeling rates (1). They are consi-
dered effective drugs in treatment of disease affecting 
bone metabolism, characterized by increased resorp-
tion, such as osteoporosis, Paget’s disease, hypercalce-
mia of malignancy, multiple myeloma and bone metas-
tasis of prostate, lung and breast cancer (2,3).
These drugs are divided into first-generation non-nitro-
gen-containing (clodronate, etidronate and tiludronate) 
and second and third generation nitrogen-containing 
(alendronate, risedronate, ibandronate and zoledronate) 
and the last ones differ from the others because they ad-
here more tightly to hydroxyapatite mineral in bone (1).
The route of administration affects the skeletal uptake of 
the medication. Oral bisphosphonates are poorly absor-
bed and present less than one percent of bioavailability, 
whereas the intravenous are completely bioavailable (1). 
Oral Bisphosphonates include alendronate, risedronate, 
etidronate, tiludronate. Pamidronate and zoledronate 
are only intravenous, whereas ibandronate and clodro-
nate are administrated by both routes (4).
One of the most serious complications of BP therapy 
is Bisphosphonate Related Osteonecrosis of the Jaws 
(BRONJ). Because of the growing number of osteone-
crosis cases in the jaws associated with other antire-
sorptive and antiangiogenic therapies, American Asso-
ciation of Oral and Maxillofacial Surgeons (AAOMS) in 
2014 suggested a nomenclature change from BRONJ to 
Medication Related Osteonecrosis of the Jaw (MRONJ) 
(5). 
Osteonecrosis induced by bisphosphonates is charac-
terized by exposed bone or bone that can be probed 
through an intraoral or extraoral fistula in the maxi-
llofacial region that has persisted for more than eight 
weeks in patients who have received current or previous 
treatment with antiresorptive or antiangiogenic agents 
and no history of radiation therapy to the jaws or metas-
tatic disease to the jaws (5). Mandible and maxilla are 
bones exposed to the external environment, through the 
teeth. First cases of BRONJ were most likely associated 
to previously tooth removal surgery or other condition 
that increases the demand for bone turnover (6).
That is why there is controversy whether it is safe to 
place implants in patients taking bisphosphonates for 
bone diseases.
This review aimed to analyze articles that studied pa-
tients who were submitted to bisphosphonate therapy 
and who received dental implants before, during or af-
ter the BP treatment. The comparison was made with 
heathy patients who did not were under BP treatment 
and the outcomes observed were possible failures and 
loss of implants and the incidence of Bisphosphonate 
Related Osteonecrosis of the Jaws.
Material and Methods
- Search Strategies
The PubMed-Medline database of the United States 
National Library of Medicine, National Institutes of 
Health, Bethesda, Maryland, was electronically sear-
ched for articles published up until April 15, 2015. The 
Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) statement was used in this 
study (7). The clinical question in “PICO” format (P = 
patient problem / population, I = Intervention, C = Com-
parison, O = Outcome) in our study was:
In patients under bisphosphonate therapy, do dental im-
plants placement, compared to healthy patients, increa-
se the failure and loss of implants or bisphosphonate 
related osteonecrosis of the jaw incidence? 
The following MeSH (Medical Subjects Headings) 
terms: “Diphosphonates”, “Dental Implants”, “Guided 
Tissue Regeneration”, “Guided Tissue Regeneration, 
Periodontal”, “Alveolar Bone Grafting”, “Subgingival 
Curettage”, “Gingivectomy”, “Bisphosphonate-Asso-
ciated Osteonecrosis of the Jaw” and their related en-
try terms were used in different combinations using the 
Boolean Operators “AND” and “OR” for the research. 
In addition, manual search was made by each one of the 
researchers.
Before starting the study, exclusion and inclusion crite-
ria were established:
- Exclusion criteria:
(a) Articles published in another language other than 
English or Portuguese; (b) experimental laboratory stu-
dies; (c) animal studies; (d) studies that the main topic 
was not the relation between dental implants and syste-
mic bisphosphonate therapy. (e) systematic reviews; (f) 
topical administration route of bisphosphonates; (g) full 
text articles were not available on the data base sear-
ched; (h) single case reports; (i) duplicated articles; (j) 
letters to editor; (k) commentaries.
- Inclusion criteria:
(a) Articles enrolled patients undergoing bisphosphona-
te therapy (oral and intravenous) and submitted to den-
tal implants procedure; (b) case series; (c) retrospective 
Studies; (d) prospective Studies.
Results
The initial search resulted in a list of 375 articles. In 
turn, titles were analyzed and based on exclusion crite-
ria only 152 abstracts were included. After reading of 
the available abstracts, 27 articles were read and two 
of them were excluded because it was observed that 
they were not in accordance with the inclusion crite-
ria described next, and eight systematic reviews were 
used only as a research source. Finally, 17 articles were 
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assessed for data extraction.  After the final evaluation 
3 papers were excluded because they did not focus on 
the relationship between dental implants and bisphos-
phonate therapy or their sample enrolled much more pa-
tient that were not under bisphosphonate treatment than 
patient under bisphosphonate therapy. Additionally, one 
article was included after manual search. Lastly, data 
from 15 studies fulfilled the inclusion criteria and were 
used to compose this systematic review (Fig. 1).
The data presented in tables 1,2: Author and year; gen-
der of patients; age of patients (years); risk factors; num-
ber of patients in the study; number of implants placed; 
number of loss of implants; follow-up period (months); 
indication, type of bisphosphonate used and route of ad-
ministration; duration of BP treatment (months); num-
ber and location of BRONJ were extracted from the 15 
selected studies.
- Studies description
Eight were retrospective studies (8-15) one was pros-
pective study (16) and six were case series (17,3,18-21). 
The articles were classified according to the levels of 
evidence (based on the University of Oxford’s Center 
for Evidence Based Medicine criteria) (22) (Table 3).
Overall, this systematic review analyzed 1339 patients 
Fig. 1. Prisma® flow diagram of the search processes and results.
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(528 patients with a history of BP use and 811 patients 
without history of BP) with 3748 implants placed (1330 
in BP users and 2418 in control patients) and 152 loss 
of implants (113 in BP users and 39 in control patients). 
Patient s´ age ranged from 17 to 91 years and most of 
them were female gender. There were 78 cases of osteo-
necrosis and the lesions occurred in mandible (53 cases), 
maxilla (23 cases) and 2 in both jaws. The majority of 
the lesions were located predominantly in the posterior 
areas (63 cases). Follow-up period ranged from 1 to 132 
months.
Ten of the studies selected presented bisphosphonate 
therapy administered orally (alendronate, risedronate, 
ibandronate) (17,3,18,8-10,12-14,20), 4 both (alendro-
nate, risedronate, pamidronate, zolendronate and iban-
dronate) (11,19,15,21) and 1 intravenously (zoledronate) 
(16). Among studies which have reported oral route of 
administration of bisphosphonate, only two (18,20) rela-
ted cases of osteonecrosis. On the other hand, one hun-
dred percent of the studies (11,19,15,21) which related 
combined use of oral and intravenous BP, have shown 
cases of osteonecrosis. Duration of BP therapy ranged 
from 3 to 192 months. Osteoporosis and malignant di-
seases were the most commonly indication for BP use.
Discussion
Given the widespread use of bisphosphonates for seve-
ral conditions and the large use of dental implants for 
Table 1. Summary of the studies meeting the eligibility criteria.
Author, year Gender
Aver-
age age 
or range 
(years)
Number 
of cases/
controls
Number of 
implants in 
BP users/
controls
Number 
of loss of 
implants
Risk 
factors
Follow-up 
(months)
Tam et al., 2014 Female 71,8 6 19 10
Hyperten-
sion, chemo-
therapy
26 (mean)
Kwon et al., 
2014
17 Female
 2 Male 42-85 19 NA 23
Hyperten-
sion and 
diabetes
24
López-Cedrún 
et al., 2013
8 Female 
1 Male 66 9 57 12
Smoking, 
hypertension 
and steroids
3-36
Siebert et al., 
2013 Female 54 12/12 60/60 None None 12
Jacobsen et al., 
2013
11 Female 
3 Male NA 12 23 12 NA NA
Memon et al., 
2012 Female 46-91 100/100 153/132 10/6
Diabetes and 
smoking NA
Zahid et al., 
2011
Female 
and Male 17-87 26/274 51/610 3/16 Smoking 26 (mean)
Koka et al., 
2010 Female > 50 55/82 121/166 1/3
Steroids, 
diabetes and 
smoking
18
Lazarovici 
et al., 2010
20 Female 
7 male 70 27 NA NA
Smoking, 
diabetes and 
steroids
3-43
Martin et al., 
2010 Female 70.2 16 44 26
Smoking 
and steroids 1-132
Shabestari 
et al., 2010 Female 53 21 46 None None 50 (mean)
Goss et al., 2010 5 Female 2 Male 65.7 7 19 9
 Diabetes 
and steroids NA
Grant et al., 
2008 Female 67,4 115/343 468/1450 2/14
Diabetes and 
steroids 48
Bell e Bell, 
2008
95% Fe-
male NA 42 100 5 Smoking 37 (mean)
Fugazzotto 
et al., 2007 Female 51-83 61 169 None NA 12-24
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treatment of partial or complete edentulism, as well as 
the increasing of cases of bisphosphonate related osteo-
necrosis of the jaw, it is of matter importance to evaluate 
the relation between these topics to find out the risks for 
the osseointegration process and BRONJ appearance.
To Holzinger et al. (23), the development of osteonecro-
sis in conjunction with dental implants might be a side 
effect of treatment with oral or intravenous BPs. The in-
cidence of BRONJ is accelerated after the conclusion of, 
or during, BP therapy. From their data, BPs could have a 
potentiating effect on peri-implantitis and implant loss.
Javed and Almas (24) showed that the incidence of im-
plant failure was minimal in patients using oral and in-
travenous bisphosphonates, and concluded that dental 
implants in patients undergoing BPs therapy can osse-
ointegrate and remain functionally stable. On the other 
hand, Mínguez-Serra et al. (25) suggested the avoidance 
of dental implant procedures in patients that have been 
receiving intravenous BPs. This is in accordance with 
the results of the present review on where one hundred 
Author, year Number of cases/controls 
Indication of 
Bisphosphonate use 
Route of 
administration 
Type of 
Bisphosphonate 
Treatment 
duration 
(months) 
Incidence of 
BRONJ (number 
of cases) 
Location of 
BRONJ 
Tam et al., 
2014 6 
Osteoporosis, 
breast cancer and 
multiple myeloma 
Oral, 
intravenous 
and both 
Alendronate, 
zoledronate and 
ibandronate 
18-72 6 
Posterior 
mandible (3), 
anterior 
mandible (1) 
and posterior 
maxilla (2) 
Kwon et al., 
2014 19 
Osteoporosis and 
multiple myeloma 
Oral and 
intravenous 
Alendronate, 
risedronate, 
zoledronate, 
ibandronate, and 
pamidronate 
60,5 
(mean) 19 
Posterior 
mandible (8), 
anterior 
mandible (1), 
posterior 
maxilla (8) and 
both posterior 
jaws (2) 
López Cedrún 
et al.,  2013 9 
Osteoporosis, 
osteoarthritis and 
polymyalgia 
rheumatica 
Oral 
Alendronate, 
risedronate and 
ibandronate 
6-120 9 
Posterior 
mandible (7) 
anterior 
mandible (1), 
and posterior 
maxilla (1) 
Siebert et al., 
2013 12/12 Osteoporosis Intravenous Zoledronate 24-36 None 
__ 
Jacobsen  
et al., 2013 12 
Osteoporosis, 
multiple myeloma, 
breast cancer, 
prostate cancer and 
lung cancer 
Oral and 
intravenous 
Alendronate, 
zoledronate, 
ibandronate, and 
pamidronate 
38-50 12 
Posterior 
mandible (5), 
anterior 
mandible (3) 
and posterior 
maxilla (4) 
Memon  
et al., 2012 100/100 Osteoporosis Oral 
Alendronate, 
risedronate and 
ibandronate 
12-36 NA NA 
Zahid et al., 
2011 26/274 Osteoporosis Oral Alendronate 6-192 None 
__ 
Koka et al., 
2010 55/82 
Osteoporosis and 
osteopenia Oral Alendronate 36-60 None 
__ 
Lazarovici  
et al., 2010 27 
Osteoporosis, 
multiple myeloma, 
breast cancer and 
prostate cancer 
Oral and 
intravenous 
Alendronate, 
zoledronate, and 
pamidronate 
16,4-68 27 
Posterior 
mandible (15), 
anterior 
mandible (5), 
posterior maxila 
(4) and anterior 
maxila (3) 
Martin et al., 
2010 16 Osteoporosis Oral Alendronate 38 (mean) None 
__ 
Shabestari  
et al., 2010 21 Osteoporosis Oral Alendronate 
20,5 
(mean)    None 
__ 
Goss et al., 
2010 7 Osteoporosis Oral 
Alendronate and 
risedronate 3-120 5 
Posterior 
mandible (3), 
anterior 
mandible (1), 
and posterior 
maxilla (1) 
Grant et al., 
2008 115/343 NA Oral 
Alendronate, 
risedronate, and 
ibandronate 
38 (mean) None __ 
Bell e Bell, 
2008 42 NA Oral 
Alendronate, 
risedronate, and 
ibandronate 
6-132 None __ 
Fugazzotto  
et al., 2007 61 Osteoporosis Oral 
Alendronate and 
risedronate 40 None 
__ 
!
Table 2. Summary of the studies presenting data about bisphosphonate related osteonecrosis of the jaws (BRONJ).
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percent of the studies (11,19,15,21) which related com-
bined use of oral and intravenous BP, have shown cases 
of osteonecrosis. In the case of administration via oral 
route, caution is required, avoiding these procedures, or 
indicating them only when absolutely necessary.
Bell and Bell (13) had a success rate of 95% in 100 den-
tal implants installed in 42 patients taking oral bisphos-
phonates and they did not present signs of osteonecrosis 
of the jaws. Therefore, they concluded that there is no 
relationship between oral medications containing BPs 
and implant failure. Others authors (3,8,9,10,14) sugges-
ted that bisphosphonates exposure and implant place-
ment do not affect implant success and do not result in 
osteonecrosis. However, their duration follow-up was 
short. These results are in accordance with other publi-
cations (24,26).
The study of Yip et al. (27) indicates that women with 
implant failure had increased odds of reporting a his-
tory of oral bisphosphonate use compared with those 
without implant failure. These findings suggest that 
dental practitioners should be aware of the increased 
risk of implant failure associated with oral bisphospho-
nate use in certain patient populations. Their conclusion 
is in agreement with the recommendation for discon-
tinuation of oral bisphosphonate therapy in long-term 
oral bisphosphonate users for 4-6 months prior to im-
plant insertion, and several months after, to allow for 
the recovery of bone remodeling (28).
Lazarovici et al. (19) followed 27 patients who develo-
ped BRONJ associated with dental implants and conclu-
ded that this condition is a side effect of BPs treatment 
presented like a late complication. They suggested that 
patients undergoing bisphosphonate therapy who recei-
ve dental implants should be followed for long periods, 
and those ones who developed BRONJ associated with 
dental implants should undergo a long-term treatment 
with doxycycline 100 to 200 mg/d, and their dental im-
plants should be removed only if the antibiotic therapy 
fails to alleviate the signs and symptoms of BRONJ. The 
duration of bisphosphonate treatment in the studies with 
cases of BRONJ ranged from 3 months up to 120 mon-
ths (reaching more than four years in the most), there-
fore all of them have shown long duration of treatment. 
This information might be related to the fact that, as 
Lazarovici el at. (19) have shown, the osteonecrosis is 
a late complication, thus the follow up period must be 
extended in order to find late signs and symptoms.
The literature reviewed say that patients who take oral 
bisphosphonates, can be submitted to dental implant 
surgery, on the condition that the risks are thoroughly 
assessed. The evaluation of the risks associated to the 
patients comprises: type of agent, dose, and duration of 
BP treatment (determinant); female gender, age greater 
than 65 years, comorbidities such as diabetes or obesity, 
tobacco abuse, concomitant treatment such as cortico-
therapy, chemotherapy, immunosuppressive therapy, 
mandibular localization, posterior area, bone diseases 
such as exostosis, or tori, harboring a badly fitted pros-
thesis (potentially aggravating), and periodontal disea-
se, bad oral and dental hygiene (aggravating) (29).
Diabetes, chemotherapy, steroids use, hypertension 
and smokers habits were the most common risk fac-
tors found among the patients enrolled on the studies. 
Implant supported dentures are great resources to re-
habilitation of edentulous areas in comparison with 
the traditional prosthetic appliances, however the bone 
condition (quantity and quality) and its healing capacity 
are factors that cannot be left without the appropriate 
attention because they can influence the success rate of 
the dental implants procedures.
The most of the studies (18,11,19,15,21) with cases of 
osteonecrosis enrolled patients with underlying disease 
such as malignant diseases, osteoarthritis and polym-
yalgia rheumatic as indication, whereas the majority 
(7,3,10,12,16) of the studies with no cases of osteone-
crosis, presented only osteoporosis as indication for BP 
therapy. This information suggests that general health 
status of the patients might also have contributed with 
the development of BRONJ.
Some authors suggest the use of the Telopeptide C ter-
minal CTX Test as a method to define the risk of deve-
lopment of osteonecrosis of the jaws in patients under-
going bisphosphonate therapy by measuring a specific 
crosslink peptide of type I collagen in bone (30,28). 
However, it is important to note that recent guidelines 
do not consider such method neither validated nor re-
commended and it has not been advisable its use (29,5).
Author, Year
Levels of evidence 
(CEMB 2011)
Siebert et al., 2013 1b
Memon et al., 2012 3b
Zahid et al., 2011 3b
Koka et al., 2010 3b
Grant et al., 2008 3b
Tam et al., 2014 4
Kwon et al., 2014 4
López-Cedrún., 2013 4
Jacobsen et al., 2013 4
Lazarovici et al., 2010 4
Martin et al., 2010 4
Shabestari et al., 2010 4
Goss et al., 2010 4
Bell e Bell, 2008 4
Fugazzotto et al., 2007 4
Table 3. Levels of clinical evidence (CEBM 2011).
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According to the AAOMS (5), individuals who have 
taken oral BP for less than four years and have no 
risk factors, do not need any alteration in the planned 
surgery. If a dental implant surgery is proposed, in-
formed consent should be provided reporting possible 
long-term implant failure and the low risk of develo-
ping osteonecrosis of the jaws. Such patients should be 
assessed on a regular dental follow-up. For those pa-
tients who have taken oral BP for less than four years 
and have also taken corticosteroids or antiangiogenic 
medications concomitantly, or for patients who have 
taken oral BP for more than four years with or without 
any concomitant medical therapy, the discontinuation 
of this drugs (drug holiday) should be considered for at 
least two months prior to surgery, if systemic conditions 
permit and bisphosphonate should not be restarted until 
osseous healing has occurred. 
Dentoalveolar surgery is considered great risk fac-
tor for the Medication Related Osteonecrosis of the 
jaw (MRONJ). It is reported that among patients with 
MRONJ 52 to 61% of patients report tooth extraction as 
the precipitating event (5). Above all, it is of matter im-
portance to be aware of the great destructive potential 
of osteonecrosis of the jaws. These lesions can cause 
large deformity in the face of the patients. The BRONJ 
can result in significant functional and aesthetic defects 
since the treatment usually involves debridement and 
resection of the affected area. 
This study analyzed 528 patients with history of BP 
use, with 1330 implants placed in these patients. The-
re were 113 loss of implants (8.49%) in BP users and 
78 cases of osteonecrosis (14.77%). These results show 
high percentages of loss of implants and notably an ele-
vate incidence of osteonecrosis. Considering these data, 
it is reasonable to be cautious during the planning of 
implant surgery for patients undergoing bisphosphonate 
therapy. And going beyond, maybe the health profes-
sionals should start to indicate dental procedures such 
as dental prophylaxis, restorations, gingival curettage, 
root scaling, endodontic treatments and extractions 
before the patients initiate the bisphosphonate therapy 
with the goal of avoid invasive dental procedures during 
the BP treatment, likewise it is done with patients who 
are going to be submitted to radiotherapy.
- Study limitation
The main limitation of our study is the lack of randomi-
zed clinical trial related to the theme, which limits the 
level of evidence of the obtained information. Moreover, 
a meta-analysis was not possible to because of the hete-
rogeneity of the studies and their presented data. 
Conclusions
Considering the limitations of this study, it is wise to be 
careful when comes the time of planning dental implant 
surgery in patients undergoing bisphosphonate therapy. 
The risk of developing BRONJ as well as occurring fail-
ure or loss of implant exists and it is greater in patients 
under intravenous bisphosphonate therapy. A complete 
medical history of the patient must be analyzed and in the 
case of the therapy with bisphosphonate be confirmed, 
the duration of treatment, as well as the route of adminis-
tration should be taking into consideration. Then, if pos-
sible, suspend the treatment based on the AAOMS rec-
ommendation.  Ultimately, further randomized clinical 
trials with longer follow-up period are needed because it 
remains unclear in what intensity the exposure to these 
medications is harmful to implant treatment.
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